Press Releases
PacBio Announces PacBio Capital
New Programme Expands Access to PacBio’s Highly Accurate Sequencing Systems by Providing Flexible Financing
14 September 2023 -- California, US -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced PacBio Capital, a programme that offers customers the ability to lease PacBio sequencing systems – Revio, Onso and Sequel IIe – easily and cost-effectively.
"Through PacBio Capital, we can expand our ability to reach customers and new markets," said Christian Henry, president and chief executive officer of PacBio. "By making it possible to lease our game-changing sequencing systems, customers can conserve capital and keep monthly payments down while continuing with their groundbreaking research."
PacBio Capital allows qualified customers to choose capital and operating lease structures with highly competitive rates and a six-month same as cash financing option. The streamlined credit and funding process can enable labs to fast-track their purchase of PacBio systems and allow more customers to benefit from the sub-$1,000 HiFi human genome on the recently released Revio system.
"It’s a win/win for PacBio and our current and future customers," said Jeff Eidel, chief commercial officer at PacBio. "With PacBio Capital, we aim to get more systems into the hands of customers faster by offering them the flexibility to lease our products under the terms that work best for them."
Visit: www.pacb.com
About PacBio
PacBio is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology and other emerging applications.
New Programme Expands Access to PacBio’s Highly Accurate Sequencing Systems by Providing Flexible Financing
14 September 2023 -- California, US -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced PacBio Capital, a programme that offers customers the ability to lease PacBio sequencing systems – Revio, Onso and Sequel IIe – easily and cost-effectively.
"Through PacBio Capital, we can expand our ability to reach customers and new markets," said Christian Henry, president and chief executive officer of PacBio. "By making it possible to lease our game-changing sequencing systems, customers can conserve capital and keep monthly payments down while continuing with their groundbreaking research."
PacBio Capital allows qualified customers to choose capital and operating lease structures with highly competitive rates and a six-month same as cash financing option. The streamlined credit and funding process can enable labs to fast-track their purchase of PacBio systems and allow more customers to benefit from the sub-$1,000 HiFi human genome on the recently released Revio system.
"It’s a win/win for PacBio and our current and future customers," said Jeff Eidel, chief commercial officer at PacBio. "With PacBio Capital, we aim to get more systems into the hands of customers faster by offering them the flexibility to lease our products under the terms that work best for them."
Visit: www.pacb.com
About PacBio
PacBio is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology and other emerging applications.
Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.